Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?

A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.San Diego-based Tang Capital Management reported that it acquired 1.3 million shares in Aurinia Pharmaceuticals (AUPH) during the third quarter, a move that helped increase its position in the stock by $40.2 million.What HappenedAccording to a Securities and Exchange Commission (SEC) filing dated November 14, Tang Capital Management, a life-sciences-focused fund,  i ...